HELP YOUR PATIENTS WITH MIGRAINE SAVE ON REYVOW
Eligible, commercially insured patients can pay as little as $0 for up to 12 months with the REYVOW Savings Card*
*Depending on patient coverage.
Savings in just a few simple steps:
aPatients need PA approved by second fill and insurance must continue to cover the claim for patients to pay as little as $0 for up to 12 months.
Please work with the patient's plan to pursue claim approval by the second fill. Patients need approval by second fill to continue to pay as little as $0 for REYVOW.
*Terms and Conditions: Offer good until 12/31/2021 for up to 12 months of REYVOW. Patients with commercial drug insurance may be able to pay as little as $0 for their first fill of REYVOW. For the 2nd and subsequent fills, patients must have coverage for REYVOW through their commercial drug insurance plan to continue to pay as little as $0 per fill. Offer subject to a monthly savings of wholesale acquisition cost plus usual and customary pharmacy charges and a separate $3,400 maximum annual savings. Participation in the program requires a valid patient HIPAA authorization. Patient is responsible for any applicable taxes, fees, or amounts exceeding monthly or annual caps. This offer is invalid for patients without commercial drug insurance or those whose prescription claims are eligible to be reimbursed, in whole or in part, by any governmental program, including, without limitation, Medicaid, Medicare, Medicare Part D, Medigap, DoD, VA, TRICARE®/CHAMPUS, or any state patient or pharmaceutical assistance program. Offer void where prohibited by law and subject to change or discontinue without notice. Card activation is required. Subject to additional terms and conditions.
Your patients can text SUPPORT to 55900 to receive a guide to savings and information on taking REYVOW, including instructions for downloading the Savings Card directly on their phone.
Message and data rates apply.
Resources For Your Practice
Get access to helpful resources as you get your patients started with REYVOW
A form to help you prescribe REYVOW for your patients.
A quick guide to completing the REYVOW prior authorization request for you and your office staff.
A sample letter to appeal coverage determination or prior authorization for a patient’s plan.
A sample letter with Letter of Medical Necessity considerations.
An overview for pharmacists that combines relevant product and savings information.
Request Representative Visit or Sample
If interested in requesting a visit from a REYVOW sales representative or a REYVOW sample pack, please complete and submit your request electronically
GET STARTED
REYVOW sample packs provide patients and healthcare professionals the opportunity to determine if REYVOW is right for the patient. Samples are used to assess the product’s efficacy and tolerability for an individual patient. Not all states accept controlled substance samples. REYVOW is a Schedule V controlled substance.
Register to Learn More
Want to learn more about REYVOW and receive updates from Lilly?
REGISTER HERE
INDICATION AND USAGE
REYVOW is indicated for the acute treatment of migraine with or without aura in adults.
Limitations of Use: REYVOW is not indicated for the preventive treatment of migraine.
IMPORTANT SAFETY INFORMATION
WARNINGS AND PRECAUTIONS
Driving Impairment
REYVOW may cause significant driving impairment. In a driving study, administration of single 50 mg, 100 mg, or 200 mg doses of REYVOW significantly impaired subjects' ability to drive. Additionally, more sleepiness was reported at 8 hours following a single dose of REYVOW compared to placebo. Advise patients not to engage in potentially hazardous activities requiring complete mental alertness, such as driving a motor vehicle or operating machinery, for at least 8 hours after each dose of REYVOW. Patients who cannot follow this advice should not take REYVOW. Prescribers and patients should be aware that patients may not be able to assess their own driving competence and the degree of impairment caused by REYVOW.
Central Nervous System Depression
REYVOW may cause central nervous system (CNS) depression, including dizziness and sedation. Because of the potential for REYVOW to cause sedation, other cognitive and/or neuropsychiatric adverse reactions, and driving impairment, REYVOW should be used with caution if used in combination with alcohol or other CNS depressants. Patients should be warned against driving and other activities requiring complete mental alertness for at least 8 hours after REYVOW is taken.
Serotonin Syndrome
In clinical trials, reactions consistent with serotonin syndrome were reported in patients treated with REYVOW who were not taking any other drugs associated with serotonin syndrome. Serotonin syndrome may also occur with REYVOW during coadministration with serotonergic drugs. Serotonin syndrome symptoms may include mental status changes, autonomic instability, neuromuscular signs, and/or gastrointestinal signs and symptoms. The onset of symptoms usually occurs within minutes to hours of receiving a new or a greater dose of a serotonergic medication. Discontinue REYVOW if serotonin syndrome is suspected.
Medication Overuse Headache
Overuse of acute migraine drugs may lead to exacerbation of headache. Medication overuse headache may present as migraine-like daily headaches or as a marked increase in frequency of migraine attacks. Detoxification of patients including withdrawal of the overused drugs and treatment of withdrawal symptoms (which often includes a transient worsening of headache) may be necessary.
ADVERSE REACTIONS
The most common adverse reactions associated with REYVOW (≥2% and greater than placebo in clinical studies) were dizziness, fatigue, paresthesia, sedation, nausea and/or vomiting, and muscle weakness.
ABUSE
REYVOW contains lasmiditan, a Schedule V controlled substance (C-V). REYVOW has abuse potential. Evaluate patients for risk of drug abuse and observe them for signs of lasmiditan misuse or abuse.
See Full Prescribing Information and Medication Guide.
LM HCP ISI 28SEP2020